Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-08T16:16:35.368Z Has data issue: false hasContentIssue false
  • English
  • Français

Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia

Published online by Cambridge University Press:  16 April 2020

M. Arato ,
R. O’Connor ,
J.E. Bradbury  and
H. Meltzer
M. Arato
Affiliation:
Kecskemeti u. 11, Budapest, H-1053, Hungary
R. O’Connor
Affiliation:
Pfizer Inc. New York, New York, NY10017-5755
J.E. Bradbury
Affiliation:
Central Research Division, Pfizer Inc, Sandwich. Kent CT13 9NJ, UK
H. Meltzer
Affiliation:
Vanderbilt University Medical Center, Nashville, TN37212, USA

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 13 , Issue S4: Standards of psychiatry - 9th Congress of Association of European Psychiatrists , 1998 , pp. 303s
Copyright
Copyright © European Psychiatric Association 1998
Submit a response

Comments

No Comments have been published for this article.